There is an unmet need for the introduction of a novel therapy that is effective in the 1L treatment of GC/GEJC/EAC soon after diagnosis, particularly for patients whose HER2 status is negative or unknown, with a prospect of achieving improved quality, as well as quantity, of life in these patients. This evidence concerns the gene ERBB2 and gastric cancer.